Form 4: United Therapeutics COO Michael Benkowitz Executes Stock Option Exercises and Sales

Michael Benkowitz, President and COO of United Therapeutics, executed stock option exercises and sales on August 7, 2024, involving both direct and indirect ownership through trusts.

Summary

• On August 7, 2024, Michael Benkowitz, the President and COO of United Therapeutics, engaged in transactions involving the company's stock.
• Benkowitz exercised stock options to acquire 5,000 shares at $111 and 20,000 shares at $120.26.
• He then sold a total of 23,700 shares at prices ranging from $321.9528 to $326.9156.
• These transactions were executed through both direct sales and sales from trusts where Benkowitz has beneficial ownership.
• Following these transactions, Benkowitz directly owns 2,577 shares and indirectly owns shares through trusts.
• He also holds derivative securities in the form of stock options.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of insider trading activity. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the actions of company executives. It's common for executives to exercise stock options and sell shares for personal financial management.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading activities.
• The reported transactions are similar to those seen by executives at comparable pharmaceutical companies such as Johnson & Johnson, Pfizer, and Amgen, where stock options are part of compensation packages.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the increased supply of shares in the market.
• The impact is likely minimal given the relatively small volume of shares traded compared to the company's overall market capitalization.

Key Dates